Role Of Pet Scan In Predicting Response To Neoadjuvant Chemotherapy And Long-Term Outcomes For Stage Ii Lung Cancer.

7574 Background: While the role of neo-adjuvant chemotherapy (NAT) in stage IIIA non-small cell lung cancer (NSCLC) is well established, its efficacy in stage II is unclear. We evaluated the role of PET scan in predicting long-term outcomes in patients with stage II NSCLC undergoing surgical resection following NAT. Methods: Clinical stage II NSCLC (7th ed. AJCC) patients that underwent NAT between 1995 and 2010 were identified using a prospectively maintained database. All patients underwent clinical staging using CT scan and PET scan, with or without invasive lymph node staging. Chemotherapy regimen was unchanged during the study period. Results: Fifty-five patients with clinical stage II were identified who received NAT prior to surgery. The mean age was 63.1±10.2. Patients were predominantly white (69%) and female (53%). Most tumors were adenocarcinomas (70%), and most patients underwent a lobectomy (87%). Seventeen patients (30%) developed temporary interruption due to side effects from NAT. The 30-d...